Phase I study of the novel oral steroidal antiestrogenic agent TAS-108, ascending single dose, safety, tolerance, and pharmacokinetic parameters in healthy postmenopausal women.

被引：0
|
作者：
Kuritani, J
Abdelhameed, M
Boyeson, M
Dixon, RM
Pfefferkorn, C
Yonezawa, J
Shindo, T
Minami, Y
Buzdar, AU
机构：
[1] Taiho Pharmaceut Co Ltd, Tokyo, Japan
[2] Covance Clin Res Unit Inc, Madison, WI USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
下载
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [31] A phase I single-rising-dose study of oral BI 1358894 in healthy male volunteers: safety, pharmacokinetics and food effect
    Fuertig, R.
    Goettel, M.
    Hoefler, J.
    Sharma, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S256 - S257
  • [32] Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.
    Mileshkin, L. R.
    Rosen, L. S.
    Blumenkopf, T.
    Breazna, A.
    Darang, S.
    Davison, J.
    Gallo, J.
    Goldman, J. W.
    Wang, D. D.
    Zhang, S.
    Eckhardt, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects
    Hernandez-Mitre, Maria Patricia
    Wallis, Steven C.
    Morgan, Elizabeth E.
    Dudley, Michael N.
    Loutit, Jeffery S.
    Griffith, David C.
    Roberts, Jason A.
    Shields, Ryan K.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (01)
  • [34] Phase 1 safety, tolerability, and pharmacokinetic study of single ascending doses of XM17 (recombinant human follicle-stimulating hormone) in downregulated healthy women
    Lammerich, Andreas
    Bias, Peter
    Gertz, Beate
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2015, 7 : 707 - 715
  • [35] A novel oral iron chelator (ICL670A):: Results of a phase I single-dose safety study.
    Piga, A
    Galanello, R
    Dessi, C
    Sedaro, M
    Loehrer, F
    Séchaud, R
    Bigler, H
    Origa, R
    Tartaglia, N
    Alberti, D
    BLOOD, 1999, 94 (10) : 35B - 35B
  • [36] A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers
    Faaij, RA
    Burggraaf, J
    Schoemaker, RC
    van Amsterdam, RGM
    Cohen, AF
    THROMBOSIS AND HAEMOSTASIS, 1999, : 490 - 491
  • [37] A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects
    Liu, Yubin
    Wang, Meixia
    Dong, Xiaona
    He, Jia
    Zhang, Lin
    Zhou, Ying
    Xia, Xia
    Dou, Guifang
    Wu, Chu-tse
    Jin, Jide
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (03):
  • [38] A phase I single-rising dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral akt inhibitor in healthy male volunteers
    Trucksis, Michele
    Friedman, Evan
    Taylor, Adekemi
    Delgado, Liliana
    Reynders, Tom
    DeSmet, Marina
    Dong, Yingwen
    Fu, Irong
    DeMeyer, Igance
    Chodakewitz, Jeffrey
    Iwamoto, Marian
    Wagner, John
    CANCER RESEARCH, 2009, 69
  • [39] Phase I, double-blind, placebo-controlled, ascending single subcutaneous dose, safety, tolerability, and pharmacokinetic study of sustained release granisetron (APF530).
    Barr, John
    O'Boyle, Erin
    Johnson, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Pharmacokinetic and Safety Profile of Ivabradine in Healthy Chinese Men: A Phase I, Randomized, Open-Label, Increasing Single- and Multiple-Dose Study
    Jiang, Juanjuan
    Tian, Lei
    Huang, Yiling
    Li, Yishi
    Xu, Li
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1933 - 1945
12345